Back to Dashboard
LXRX · Healthcare

LEXICON PHARMACEUTICALS INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Bearish — money moving out

No standout activity across the feeds we track.

Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in LEXICON PHARMACEUTICALS INC? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$991M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2…

Who's behind the signal
Every informed buyer we can see on LXRX, across all three feeds.
Hedge funds · 4
Point72 (Steve Cohen) New position
Citadel Advisors Decreased −35%
AQR Capital Management Decreased −52%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. LEXICON PHARMACEUTICALS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
1
New positions
1
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
New position
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.0×
Increased +26%
% of portfolio
0.0%
Position change
+26%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
Decreased −35%
% of portfolio
0.0%
Position change
−35%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
Decreased −52%
% of portfolio
0.0%
Position change
−52%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to LEXICON PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell LEXICON PHARMACEUTICALS INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime